A new phase 3 study shows that Semaglutide (Ozempic/Wegovy) doesn’t just lead to weight loss — it also improves liver health in patients with MASH (metabolic dysfunction-associated steatohepatitis). The findings included:
- 63 % of patients had resolution of inflammation without worsened fibrosis (vs 34 % in the placebo group)
- 37 % had decreased fibrosis (vs 22 % in placebo)
- On average, patients lost more than 10 % of their weight
This strengthens the view of GLP-1 agonists as much more than “just weight loss” — they impact central risk factors for long-term health. At our clinic we see daily how these innovations change lives — not only by the scale, but also via blood pressure, liver fat and metabolic markers. More and more evidence suggests that GLP-1 may be the closest thing we have today to a true longevity drug.
